Northside Capital Management’s AbbVie ABBV Stock Holding History

Northside Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.84M	Hold	11,267	–	–	0.23%	72
2026 Q1	$2.45M	Hold	11,267	–	–	0.22%	78
2025 Q4	$2.57M	Hold	11,267	–	–	0.22%	72
2025 Q3	$2.61M	Hold	11,267	–	–	0.24%	70
2025 Q2	$2.09M	Hold	11,267	–	–	0.16%	70
2025 Q1	$2.36M	Buy	11,267 +92	+0.8%	+$17.9K	0.38%	30
2024 Q4	$1.99M	Hold	11,175	–	–	0.53%	30
2024 Q3	$2.21M	Hold	11,175	–	–	0.34%	30
2024 Q2	$1.92M	Hold	11,175	–	–	0.33%	32
2024 Q1	$2.03M	Hold	11,175	–	–	0.36%	30
2023 Q4	$1.73M	Hold	11,175	–	–	0.54%	31
2023 Q3	$1.67M	Hold	11,175	–	–	0.38%	31
2023 Q2	$1.51M	Hold	11,175	–	–	0.52%	28
2023 Q1	$1.78M	Hold	11,175	–	–	0.48%	25
2022 Q4	$1.81M	Buy	11,175 +319	+3%	+$48.9K	0.54%	25
2022 Q3	$1.46M	Hold	10,856	–	–	0.47%	28
2022 Q2	$1.66M	Hold	10,856	–	–	0.53%	23
2022 Q1	$1.76M	Hold	10,856	–	–	0.47%	25
2021 Q4	$1.47M	Sell	10,856 -258	-2%	-$30.5K	0.39%	31
2021 Q3	$1.2M	Hold	11,114	–	–	0.33%	37
2021 Q2	$1.25M	Hold	11,114	–	–	0.31%	34
2021 Q1	$1.2M	Sell	11,114 -199	-2%	-$21.3K	0.33%	35
2020 Q4	$1.21M	Sell	11,313 -1,516	-12%	-$146K	0.36%	28
2020 Q3	$1.12M	Hold	12,829	–	–	0.37%	33
2020 Q2	$1.26M	Buy	12,829 +143	+1%	+$12.6K	0.44%	30
2020 Q1	$967K	Hold	12,686	–	–	0.47%	31
2019 Q4	$1.12M	Hold	12,686	–	–	0.38%	33
2019 Q3	$961K	Sell	12,686 -1,232	-9%	-$84.5K	0.34%	36
2019 Q2	$1.01M	Buy	13,918 +110	+0.8%	+$8.65K	0.4%	27
2019 Q1	$1.11M	Buy	13,808 +270	+2%	+$22.1K	0.44%	27
2018 Q4	$1.25M	Buy	13,538 +852	+7%	+$74.9K	0.55%	20
2018 Q3	$1.2M	Sell	12,686 -1,670	-12%	-$158K	0.43%	23
2018 Q2	$1.33M	Sell	14,356 -540	-4%	-$52.7K	0.47%	21
2018 Q1	$1.41M	Buy	14,896 +155	+1%	+$17K	0.46%	22
2017 Q4	$1.43M	Hold	14,741	–	–	0.41%	24
2017 Q3	$1.31M	Buy	14,741 +1,355	+10%	+$103K	0.55%	20
2017 Q2	$971K	Sell	13,386 -1,375	-9%	-$92.4K	0.42%	23
2017 Q1	$962K	Hold	14,761	–	–	0.26%	46
2016 Q4	$924K	Buy	14,761 +325	+2%	+$19.8K	0.33%	23
2016 Q3	$910K	Buy	14,436 +1,050	+8%	+$68K	0.35%	23
2016 Q2	$829K	Buy	13,386 +362	+3%	+$22.1K	0.39%	24
2016 Q1	$744K	Buy	13,024 +3,867	+42%	+$216K	0.47%	22
2015 Q4	$542K	Hold	9,157	–	–	0.41%	27
2015 Q3	$498K	Sell	9,157 -1,595	-15%	-$104K	0.38%	28
2015 Q2	$722K	Buy	10,752 +1,595	+17%	+$104K	0.49%	23
2015 Q1	$536K	Hold	9,157	–	–	0.36%	28
2014 Q4	$599K	Buy	+9,157	New	+$577K	0.43%	25

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northside Capital Management's ABBV Position: Q2 2026 in Review

Northside Capital Management held its AbbVie (ABBV) position steady in Q2 2026 at 11,267 shares worth $2.84M. The position accounts for 0.23% of the portfolio, ranked #72.

Northside Capital Management first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. 4,208 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Northside Capital Management held 11,267 shares of AbbVie worth $2.84M as of Q2 2026.
Northside Capital Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.23% of Northside Capital Management's portfolio in Q2 2026, its #72 holding.
Northside Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
4,208 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Northside Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.